Markets:

Overview

News

Currencies

International

Treasuries

Quest Diagnostics (NY:DGX)

202.41 -0.03 (-0.01%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Quest Diagnostics

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

AMC Entertainment Tops The List Of High-Yielding Corporate Bonds — A Look At Yields As Bond Appetites Grow ↗

March 18, 2024

Benzinga used Public.com's bond screener tool to identify some of the highest-yielding investment-grade corporate bonds.

Via Benzinga

Topics Bonds

(DGX) - Analyzing Quest Diagnostics's Short Interest ↗

March 05, 2024

Via Benzinga

Why NYSE:DGX provides a good dividend, while having solid fundamentals. ↗

February 27, 2024

Balancing Dividends and Fundamentals: The Case of QUEST DIAGNOSTICS INC (NYSE:DGX).

Via Chartmill

Breaking Down Quest Diagnostics: 7 Analysts Share Their Views ↗

February 26, 2024

Via Benzinga

Spotify To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

February 07, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Is NYSE:DGX suited for dividend investing? ↗

February 05, 2024

Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential.

Via Chartmill

Beyond The Numbers: 7 Analysts Discuss Quest Diagnostics Stock ↗

February 02, 2024

Via Benzinga

Earnings Outlook For Quest Diagnostics ↗

January 31, 2024

Via Benzinga

Earnings Scheduled For February 1, 2024 ↗

February 01, 2024

Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...

Via Benzinga

Expert Ratings for Quest Diagnostics ↗

December 07, 2023

Via Benzinga

Investor Sentiment Falls Sharply Following Fed's Rate Decision; Dow Dips Over 300 Points ↗

February 01, 2024

The CNN Money Fear and Greed index showed a sharp decline in the overall market sentiment, while the index remained in the "Greed" zone on Wednesday.

Via Benzinga

Topics Economy Stocks

Quest Diagnostics Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

February 01, 2024

Quest Diagnostics Incorporated (NYSE: DGX) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 1, 2024.

Via Benzinga

The Top 3 Stocks in the High-Potential ‘Cancer Testing’ Market ↗

January 18, 2024

With the value of the cancer testing market expected to soar over the next decade, here are the three best disease testing stocks to buy now.

Via InvestorPlace

Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns ↗

January 12, 2024

A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection.

Via Benzinga

Consulting Firm McKinsey Concludes Opioid Litigation Settlement With $78M Agreement ↗

January 02, 2024

Consulting giant McKinsey & Co, on Friday, agreed to a settlement of $78 million to resolve allegations tied to the opioid epidemic, as disclosed in federal court papers filed in San Francisco.

Via Benzinga

Expert Ratings for Quest Diagnostics ↗

November 17, 2023

Via Benzinga

Quest Diagnostics Gains Momentum: Analyst Highlights Strong Business Trends And Growth Opportunities ↗

December 20, 2023

Truist Securities analyst David S.

Via Benzinga

Supreme Court Set to Decide Future of Mifepristone: Showdown Looms Over FDA's Endorsement ↗

December 13, 2023

The U.S. Supreme Court is set to deliberate on the future of mifepristone, a crucial drug employed in over half of all abortions within the U.S.

Via Benzinga

Opioid Crisis and Corporate Accountability: Purdue's Settlement in the Spotlight ↗

December 04, 2023

The U.S. Supreme Court is reviewing a contentious bankruptcy settlement involving Purdue Pharma, the maker of OxyContin, and its owners, the Sackler family.

Via Benzinga

Topics Bankruptcy

Half Of S&P 500 Stocks Still Below 200-Day Average, Ignoring Covid-Like Rally: 10 Bargain Plays For Latecomer Bulls ↗

November 21, 2023

Explore the dichotomy in the latest S&P 500 rally: Strong overall performance masks the underperformance of nearly half its stocks.

Via Benzinga

Topics Stocks

Firing on All Cylinders Indeed ↗

November 11, 2023

Investors are seeing some big reactions to earnings results in tech and have a few reasons to think some beaten-up names might be finding their footing.

Via The Motley Fool

Quest Diagnostics Q3: 7.7% Topline Decline, Earnings Beat, Updated Guidance & More ↗

October 24, 2023

Quest Diagnostics Incorporated (NYSE: DGX) posted Q3 FY23 adjusted EPS of $2.22, down 5.9% Y/Y, beating the

Via Benzinga

Topics Earnings

Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗

October 11, 2023

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...

Via Benzinga

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗

September 21, 2023

In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.

Via Benzinga

3 Pharma Stocks to Buy as Summer COVID Cases Spike ↗

August 23, 2023

Covid cases are on the rise, which might be the booster shot these top pharma stocks for Covid need to regain their trajectory.

Via InvestorPlace

Why Bionano Genomics Stock Tanked Today ↗

August 14, 2023

A CFO departure shines a light on some of the company's recent struggles.

Via The Motley Fool

More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection ↗

August 09, 2023

Alzheimer's is a huge problem, and earlier detection could make a big difference.

Via The Motley Fool

Looking for a Bargain? 3 Stocks to Buy That Are Down 10% in 2023 ↗

August 02, 2023

Investors looking for bargain stock opportunities in a rapidly-rising market should consider these companies that haven't yet bounced back.

Via InvestorPlace

Quest Diagnostics Stock Falls on Lower Q2 Revenue and Profits from Lower Productivity Effects, Tightened Outlook ↗

July 26, 2023

Quest Diagnostics Inc (NYSE: DGX) posted Q2 FY23 adjusted EPS of $2.30, down 2.5% Y/Y, beating the consensus of $2.27.

Via Benzinga

Sustaining Growth Momentum: Quest Diagnostics Continues to Excel and Reports Rising Profits ↗

July 25, 2023

At the end of July 25, 2023, Quest Diagnostics (NYSE:DGX) will reward its shareholders with a dividend payout of $0.71 per share, demonstrating an annualized dividend yield of 2.15%. Remember, only...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Quest Diagnostics (NY:DGX)

Headline News about Quest Diagnostics

Starting at $3.75/week.

Subscribe Today